CL2020市場：市場規模、予測、新たな洞察-2032年

CL2020は、東北大学の出澤真理教授を中心とする研究グループによって発見されたMuse細胞（多系統分化ストレス耐久細胞）を基にした製品です。現在、6つの適応症（急性心筋梗塞、脳梗塞、表皮水疱症、脊髄損傷、筋萎縮性側索硬化症（ALS）、SARS-CoV-2感染に伴う急性呼吸窮迫症候群（ARDS））を対象に臨床試験を進めています。一方、ライフサイエンス研究所殿町細胞加工センターは、2019年7月に再生医療等製品製造許可を取得し、製品の上市に向けた準備を進めています。

生命科学研究所は、第I/II相探索臨床試験の結果に基づき、2019年12月にCL2020のST上昇型AMI患者を対象とした第II/III相確認臨床試験を開始しました。試験は日本で実施されています。

今後数年間で、心筋梗塞の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病態を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、CL2020の優位性に影響を与える可能性のある機会を模索しています。心筋梗塞に対する他の新興製品は、CL2020に厳しい市場競争をもたらすことが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、日本における心筋梗塞治療薬のCL2020市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 心筋梗塞におけるCL2020の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 CL2020市場評価

• 心筋梗塞におけるCL2020の市場見通し
• 日本市場分析
  • 日本の心筋梗塞治療薬CL2020の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: CL2020, Clinical Trial Description, 2023
• Table 2: CL2020, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: CL2020 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: CL2020 Market Size in Japan, USD million (2019-2032)

"CL2020 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about CL2020 for myocardial infarction in Japan. A detailed picture of the CL2020 for myocardial infarction in Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the CL2020 for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CL2020 market forecast analysis for myocardial infarction in Japan, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Drug Summary:

CL2020 is a product based on Muse cells (multilineage-differentiating stress enduring cells), which were discovered by a group of scientists led by Professor Mari Dezawa of Tohoku University. The product is currently progressing with clinical trials for six indications (acute myocardial infarction, cerebral infarction, epidermolysis bullosa, spinal cord injury, amyotrophic lateral sclerosis [ALS], and acute respiratory distress syndrome [ARDS] related to SARS-CoV-2 infection). Meanwhile, Life Science Institute Tonomachi Cell Processing Center obtained a license for manufacturing regenerative medicine products in July 2019 and is preparing to launch products to the market.

Based on the results of Phase I/II exploratory clinical trial, Life Science Institute started a confirmatory Phase II/III clinical trial for CL2020 in patients with ST-elevation AMI in December 2019. The trial is being conducted in Japan.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the CL2020 description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
• Elaborated details on CL2020 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CL2020 research and development activities in myocardial infarction across the Japan.
• The report also covers the patents information with expiry timeline around CL2020.
• The report contains forecasted sales of CL2020 for myocardial infarction till 2032.
• Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
• The report also features the SWOT analysis with analyst views for CL2020 in myocardial infarction.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CL2020 Analytical Perspective by DelveInsight

• In-depth CL2020 Market Assessment

This report provides a detailed market assessment of CL2020 for myocardial infarction in Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• CL2020 Clinical Assessment

The report provides the clinical trials information of CL2020 for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CL2020 dominance.
• Other emerging products for myocardial infarction are expected to give tough market competition to CL2020 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CL2020 in myocardial infarction.
• Our in-depth analysis of the forecasted sales data of CL2020 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CL2020 in myocardial infarction.

Key Questions:

• What is the product type, route of administration and mechanism of action of CL2020?
• What is the clinical trial status of the study related to CL2020 in myocardial infarction and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CL2020 development?
• What are the key designations that have been granted to CL2020 for myocardial infarction?
• What is the forecasted market scenario of CL2020 for myocardial infarction?
• What are the forecasted sales of CL2020 in Japan?
• What are the other emerging products available and how are these giving competition to CL2020 for myocardial infarction?
• Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?

Table of Contents

1. Report Introduction

2. CL2020 Overview in myocardial infarction

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. CL2020 Market Assessment

• 5.1. Market Outlook of CL2020 in myocardial infarction
• 5.2. Japan Analysis
  • 5.2.1. Market Size of CL2020 in the Japan for myocardial infarction

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options